Survival:9.4 months
Toxicity Grade:4
Treatments:Chemotherapy
Drugs:Gemzar
Platinol
Country:Netherlands
City/State/Province:Rotterdam
Hospital:University Hospital Rotterdam
Journal:Link
Date:2/2002
Description:
Patients: This Phase II trial involved 32 patients with malignant pleural mesothelioma. None of these patients had received prior chemotherapy.

Treatment: The treatment consisted of two chemotherapy drugs, gemcitabine (gemzar) and cisplatin (platinol).

Toxicity: Grade 4 toxicities included nausea and vomiting. Grade 3 toxicities included hematologic, nausea and vomiting, fatigue anorexia, diarrhea, neurotoxicity, cardiovascular.

Results: The median survival from the start of treatment was 9.4 months.

Support: This study was supported in part by Lilly BV. Lilly markets gemzar.

Correspondence: JP van Meerbeeck, MD